A Phase 2 Study of NKT2152 Plus Palbociclib in People With Advanced Kidney Cancer


Full Title

A Phase 2 Trial to Evaluate The Safety And Efficacy Of NKT2152 in Combination with Palbociclib (Doublet) and with Palbociclib and Sasanlimab (Triplet) in Subjects with Advanced or Metastatic Clear Cell Renal Cell Carcinoma


Researchers are assessing different doses of NKT2152 that can be given with palbociclib in people with advanced kidney cancer. Both drugs are taken orally (by mouth). The people in this study have clear cell renal cell carcinoma that spread or keeps growing even after up to 4 other treatments.  

NKT2152 blocks the action of HIF2a, a protein that boosts cancer cell growth. Palbociclib is a kinase inhibitor. Kinase inhibitors block cancer cell proteins. In this case, the target is a family of kinases called CDK4/6. When HIF2a and CDK4/6 are blocked, your cancer may stop growing or it may grow more slowly, and tumors may shrink.

Who Can Join

To join this study, there are a few conditions. You must:

  • Have advanced clear cell renal cell carcinoma that keeps growing after treatment.
  • Have had treatment that included an anti-VEGF medication and immunotherapy.
  • Not have had more than 4 prior regimens of therapy.
  • Have recovered from the serious side effects of previous treatments before getting the study therapy.
  • Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
  • Be age 18 or older.



For more information and to see if you can join this study, please call Dr. Martin Voss’ office at 646-888-4721.




Phase II (phase 2)



ClinicalTrials.gov ID